Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527262 | 0.80 | CCR4 (0.64) | CCR4KDM4EEP300CA12CA9 | |
| SCHEMBL179796 | 0.80 | CCR4 (0.64) | CCR4KDM4EEP300CA12CA9 | |
| SCHEMBL13730668 | 0.78 | HSP90AA1 (0.30) | EP300HSP90AA1MGLL | |
| SCHEMBL7750137 | 0.66 | EP300 (0.78) | CCR4KDM4EEP300CA12CA9 | |
| SCHEMBL3363523 | 0.66 | EP300 (0.69) | CCR4KDM4EEP300ALDH1A1HPGD | |
| SCHEMBL4534137 | 0.63 | EP300 (0.43) | CCR4KDM4EEP300ALDH1A1HPGD | |
| SCHEMBL10881037 | 0.63 | CCR4 (0.62) | CCR4KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL10433675 | 0.63 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL3759716 | 0.63 | MGLL (0.65) | KDM4EALDH1A1HSD17B10MAPTNPSR1 | |
| SCHEMBL5048528 | 0.61 | GAA (0.35) | CCR4KDM4EEP300ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076072-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-8026057-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-7282327-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-12297221-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-11993772-B2 | Linking sequence reads using paired code tags | ILLUMINA, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008567-B2 | Oligonucleotide replacement for di-tagged and directional libraries | ILLUMINA, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3722423-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | Illumina, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-4318707-A | IMMUNOASSAY EMPLOYING ABSORPTION PARTICLES | SYVA COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0046004-A1 | Concentrating zone method in heterogeneous immunoassays | SYVA COMPANY (US) | 1982-02-17 | — | — | EP | disclosed |
| US-4281061-A | DETECTABLE SIGNAL FROM FLUORESCENT DYE OR LABELED ENZYME | SYVA COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4272506-A | BINDING A LABELED MEMBER OF A SPECIFIC BINDING PAIR TO A MERCAPTO-ACTIVATED SUPPORT THROUGH CLEAVABLE DISULFIDE LINKAGES; IMMUNOASSAY; ACCURACY | SYVA COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
| US-4256834-A | REPRESSING THE SIGNALS PRODUCED BY UNBOUND LABELS; SENSITIVITY | SYVA COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0017908-A1 | A method for determining the presence in a sample of an analyte and a kit for use in this method | SYVA COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| EP-0015695-A1 | Support-ligand analog-fluorescer conjugate and serum assay method involving such conjugate | SYVA COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
| US-4193983-A | Labeled liposome particle compositions and immunoassays therewith | SYVA COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | CCR4 1019/4885KDM4E 931/4885EP300 1847/4885 |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CCR4 1019/4885KDM4E 931/4885EP300 1847/4885 |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | CCR4 1019/4885KDM4E 931/4885EP300 1847/4885 |
| US-12297221-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CCR4 1019/4885KDM4E 931/4885EP300 1847/4885 |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CCR4 1019/4885KDM4E 931/4885EP300 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.